期刊文献+

大剂量干扰素α-2b治疗恶性黑色素瘤诱导期不良反应的观察与护理 被引量:5

下载PDF
导出
摘要 目的探讨并改进应用大剂量干扰素α-2b治疗恶性黑色素瘤时发生不良反应的护理措施。方法回顾性分析56例恶性黑色素瘤患者在接受大剂量干扰素α-2b治疗中的不良反应及其护理措施。结果 56例患者在接受大剂量干扰素α-2b诱导治疗过程中均出现不同程度的不良反应。而经过密切观察和精心护理能有效地减少不良反应。结论在临床应用大剂量干扰素α-2b治疗恶性黑色素瘤的过程中,应密切观察其不良反应,制定周密而有效的护理计划,积极干预和防治能有效的减少不良反应的发生。
机构地区 湖南省肿瘤医院
出处 《当代护士(中旬刊)》 2014年第8期92-94,共3页 Modern Nurse
基金 2010年卫生部国家临床重点专科护理专业建设项目
  • 相关文献

参考文献7

二级参考文献33

  • 1王鸿军,贾冀川.干扰素治疗病毒性肝炎的副作用及护理[J].传染病临床与研究,1996,9(1):32-33. 被引量:5
  • 2赵伟,易永祥.慢性丙型肝炎的规范化治疗及其进展[J].实用临床医药杂志,2007,11(3):13-17. 被引量:11
  • 3Hauschild A. Adjuvant interferon alfa for melanoma: new evidence--based treatment recommendations[J]? Curr Oncol, 2009, 16 (3): 3--6.
  • 4Kirkwood JM, Strawderman MH, Emstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684[J].J Clin Oncol, 1996, 14(1): 7-17.
  • 5KirkwoodJM, IbrahimJG, SosmanJA, et al. High--dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage ⅡB-Ⅲ melanoma: results of intergroup trial E1694/S9512/C509801[J].J Clin Oncol, 2001, 19(9): 2370-2380.
  • 6Kirkwood JM, Bender C, Agarwala S, et al. Mechanisms and management of toxlcifies associated with high-dose interferon alfa-2b therapy[J].J Clin Oncol, 2002, 20(17): 3703--3718.
  • 7Grob JJ, Dreno B, de la Salmoniere P, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma[J]. Lancet, 1998, 351 (9120): 1905-1910.
  • 8Pehamberger H, Soyer HP, Steiner A, et al. Adjuvant interferon alfa--2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group[]]. J Clin Oncol, 1998, 16(4): 1425-1429.
  • 9Hancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended--duration interferon alfa-2a in high-risk resected malignant melanoma[J].J Clin Oncol, 2004, 22(1): 53-61.
  • 10Kleeberg UR, Suciu S, Bracket EB, et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial, rIFN-alpha2b versus rIFN--gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 ram) or regional lymph node metastasis[J]. Eur J Cancer, 2004, 40(3): 390--402.

共引文献20

同被引文献42

  • 1张艳丽,祝顺琴,刘亚玲,崔红娟.恶性黑色素瘤内科治疗研究进展[J].肿瘤防治研究,2014,41(1):74-78. 被引量:13
  • 2刘佳,周麟,侯梅.干扰素α在恶性黑色素瘤术后患者治疗中的研究进展[J].华西医学,2006,21(2):429-430. 被引量:3
  • 3Quinn CC,Port CL,Zimmerman S,et al. Short stay nursing home rehabilitation patients:transitional care problems pose research challenges[J]. J Am Geriatr Soc ,2008,56(10) : 1940-1945.
  • 4严朝娴,邵红岩,邵双玲.大剂量干扰素辅助治疗黑色素瘤的观察与护理[J].中国实用护理杂志,2011,30(增刊):20.
  • 5Eggermont AM.Randomized trials in melanoma:an update[J]. Surg Oncol Clin N Am,2006,15(2):439-451.
  • 6Tawbi HA, Beumer JH, Tarhini AA, et al. Safety and effi- cacy of decitabine in combination with temozolomide in metastatic melanoma: A phase Ⅰ/ Ⅱ study and pharma- cokinetic analysis[J]. Ann Oncol, 2013,24 (4) : 1112.
  • 7Payne MJ,Argyropoulou K,Lorigan P,et al. Phase Ⅱ pi- lot study of intravenous high-dose interferon with or without main-tenance treatment in melanoma at high risk of recurrence[J]. J Clin Oneol,2014,32(3) : 185-190.
  • 8Ma C,Armstrong AW. Severe adverse events from the treatment of advanced melanoma:A systematic review of severe side effects associated with ipilimumab,vemu- rafenib,interferon alfa-2b,dacarbazine and intedeukin-2[J]. J Dermatolog, Treat, 2014,25 (5) : 401-408.
  • 9乌新春,段晰所.恶性黑色素瘤的研究进展[J].承德医学院学报,2008,25(3):309-312. 被引量:8
  • 10鲁元刚,杨亚东,朱堂友,杨宏珍,伍津津,杨涛.手术切除联合重组α-2b干扰素治疗肢端恶性黑素瘤15例[J].中华皮肤科杂志,2008,41(9):591-593. 被引量:3

引证文献5

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部